Charles River Laboratories Stock-Based Compensation 2010-2025 | CRL

Charles River Laboratories stock-based compensation for the twelve months ending June 30, 2025 was $0.166B, a 5.02% decline year-over-year.

  • Charles River Laboratories annual stock-based compensation for 2024 was $0.07B, a 2.99% decline from 2023.
  • Charles River Laboratories annual stock-based compensation for 2023 was $0.072B, a 2.13% decline from 2022.
  • Charles River Laboratories annual stock-based compensation for 2022 was $0.074B, a 3% increase from 2021.

Charles River Laboratories Stock-Based Compensation 2010-2025 | CRL

  • Charles River Laboratories annual stock-based compensation for 2024 was $0.07B, a 2.99% decline from 2023.
  • Charles River Laboratories annual stock-based compensation for 2023 was $0.072B, a 2.13% decline from 2022.
  • Charles River Laboratories annual stock-based compensation for 2022 was $0.074B, a 3% increase from 2021.
Related Stocks
Company NameMarket
Cap
Danaher (DHR)$151.9B
CVS Health (CVS)$90B
Elevance Health (ELV)$70.3B
Cencora (COR)$57.1B
DiDi Global (DIDIY)$27.2B
Labcorp Holdings (LH)$22.9B
Natera (NTRA)$22B
BioMerieux (BMXMF)$18B
EUROFINS SCIENT (ERFSF)$15.5B
ICON (ICLR)$14.5B
Medpace Holdings (MEDP)$13B
CochLear (CHEOY)$12.6B
Solventum (SOLV)$12.5B
Viatris (VTRS)$12.5B
Revvity (RVTY)$10.6B
Caris Life Sciences,�Inc (CAI)$10.4B
Sonic Healthcare (SKHHY)$9.3B
Avantor (AVTR)$8.8B
HealthEquity (HQY)$7.8B
Bausch + Lomb (BLCO)$5.2B
Sotera Health (SHC)$4.6B
BrightSpring Health Services (BTSG)$4.1B
Amplifon S.p.A (AMFPF)$3.9B
GeneDx Holdings (WGS)$3.5B
Surgery Partners (SGRY)$3B
Alignment Healthcare (ALHC)$3B
Concentras Parent (CON)$2.9B
Organon (OGN)$2.4B
Premier (PINC)$2.2B
Progyny (PGNY)$2B